爱普瑞克对牛皮蝇三期幼虫驱除疗效试验

为对自然感染牛皮蝇蛆病的黄牛用爱普瑞克制剂进行驱虫疗效观察,本试验设爱普瑞克Ⅰ、Ⅱ、Ⅲ号注射液7个组,空白对照1个组,依据黄牛胸围和体长,按通常采用的黄牛体重估计公式,估算每头牛的体重,皮下注射药物。结果表明:Ⅰ号制剂剂量0.5mg/kg、1.0mg/kg、1.5mg/kg,Ⅱ号制剂剂量1.0mg/kg,Ⅲ号制剂剂量1.0mg/kg,注药后第30d全部瘤疱隆起消失,牛恢复健康。结论为爱普瑞克制剂剂量在1.0mg/kg以上或爱普瑞克Ⅰ号、Ⅲ号注射液剂量在0.5mg/kg时,驱治牛皮蝇蛆病效果极好,但爱普瑞克Ⅱ号注射液剂量0.5mg/kg,治疗牛皮蝇蛆病效果欠佳。     

Efficacy of eprinomectin against Toxacara canis in dogs

This study was made to investigate efficacy of eprinomectin against to Toxocara canis in dogs. In the study, 20 stray dogs naturally infected with T. canis were divided into two groups as treatment (ten dogs) and control (ten dogs). Eprinomectin (100 μg/kg, Eprinex 250 ml) was given to treatment group dogs orally, and eggs per gram were determined in the faeces on the day of pre-treatment and the second, fourth, sixth, eighth and tenth days of post-treatment. No side effects associated with nervous, respiratory, gastrointestinal systems and some haemotological parameters were observed. In conclusion, eprinomectin was determined to be 100% effectual against T. canis.     

An automated method for the determination of subnanogram concentrations of eprinomectin in bovine plasma

Eprinomectin is a potent anthelmintic compound that kills certain parasitic nematodes and arthropods of cattle. A sensitive and automated bioanalytical assay was developed for quantitation of eprinomectin in bovine plasma in support of clinical development of eprinomectin for use in all classes of cattle. This assay determined the concentration of eprinomectin in plasma by reversed-phase high performance liquid chromatography (HPLC) with fluorometric detection. Plasma sample preparation included liquid extraction performed by the Packard MultiPROBE robotics workstation, followed by solid phase extraction performed by the Gilson ASPEC XL automated workstation. The HPLC assay included automated pre-column derivatization with a fluorogenic reagent system which included trifluoroacetic anhydride and N-methylimidazole as the catalyst. This reversed-phase chromatographic analysis was based on the fluorescence detection of derivatized eprinomectin and an internal standard, L-648 548, which was similarly derivatized by the fluorogenic reagents. The assay was automated and validated for two concentration ranges of 0.05–10 and 0.5–200 ng ml⁻¹. The lower limit of quantitation of eprinomectin in plasma was 0.05 ng ml⁻¹. The %RSD of the assay was 10% or better at all concentrations. This automated analysis of eprinomectin was used for high-throughput clinical assays with acceptable accuracy and precision.